 Aytan Musayeva
Concepts (162)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epithelium, Corneal | 6 | 2021 | 9 | 2.570 |
Why?
| | Cornea | 13 | 2024 | 52 | 2.090 |
Why?
| | Corneal Transplantation | 7 | 2024 | 7 | 1.910 |
Why?
| | Corneal Edema | 3 | 2023 | 4 | 1.270 |
Why?
| | Visual Acuity | 6 | 2020 | 135 | 1.260 |
Why?
| | Dry Eye Syndromes | 3 | 2022 | 8 | 1.210 |
Why?
| | Retina | 3 | 2021 | 64 | 1.090 |
Why?
| | Corneal Diseases | 4 | 2023 | 12 | 1.040 |
Why?
| | Endothelium, Corneal | 3 | 2022 | 4 | 0.980 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 2 | 2022 | 2 | 0.950 |
Why?
| | Keratoconus | 1 | 2021 | 4 | 0.810 |
Why?
| | Pentacyclic Triterpenes | 1 | 2021 | 8 | 0.800 |
Why?
| | Protective Agents | 1 | 2021 | 14 | 0.790 |
Why?
| | Goblet Cells | 1 | 2021 | 2 | 0.790 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2021 | 7 | 0.780 |
Why?
| | Conjunctiva | 1 | 2021 | 13 | 0.780 |
Why?
| | Limbus Corneae | 2 | 2020 | 6 | 0.770 |
Why?
| | Fuchs' Endothelial Dystrophy | 1 | 2020 | 2 | 0.740 |
Why?
| | Reperfusion Injury | 1 | 2021 | 87 | 0.740 |
Why?
| | Acanthamoeba Keratitis | 1 | 2020 | 1 | 0.740 |
Why?
| | Eye Infections, Parasitic | 1 | 2020 | 2 | 0.740 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 121 | 0.720 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2018 | 15 | 0.650 |
Why?
| | Mice, Inbred C57BL | 8 | 2024 | 1816 | 0.590 |
Why?
| | Mice | 14 | 2024 | 5739 | 0.530 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2024 | 86 | 0.500 |
Why?
| | Graft Rejection | 3 | 2024 | 161 | 0.490 |
Why?
| | Tears | 4 | 2022 | 10 | 0.480 |
Why?
| | Cell Proliferation | 1 | 2018 | 1007 | 0.480 |
Why?
| | Animals | 17 | 2024 | 13187 | 0.480 |
Why?
| | Arterioles | 3 | 2019 | 33 | 0.380 |
Why?
| | Mice, Inbred BALB C | 4 | 2024 | 304 | 0.380 |
Why?
| | Reactive Oxygen Species | 3 | 2021 | 408 | 0.370 |
Why?
| | Corneal Opacity | 2 | 2020 | 2 | 0.370 |
Why?
| | Astigmatism | 2 | 2020 | 5 | 0.370 |
Why?
| | Mice, Knockout | 4 | 2021 | 841 | 0.350 |
Why?
| | Retrospective Studies | 8 | 2022 | 6108 | 0.350 |
Why?
| | Retinal Diseases | 2 | 2019 | 49 | 0.310 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2019 | 78 | 0.300 |
Why?
| | Vasodilation | 2 | 2019 | 96 | 0.300 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3129 | 0.300 |
Why?
| | Male | 13 | 2024 | 25241 | 0.290 |
Why?
| | Graft Survival | 2 | 2024 | 150 | 0.280 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2182 | 0.280 |
Why?
| | Integrin alpha Chains | 1 | 2024 | 11 | 0.250 |
Why?
| | Th1 Cells | 1 | 2024 | 52 | 0.240 |
Why?
| | Refraction, Ocular | 2 | 2022 | 7 | 0.240 |
Why?
| | Tomography, Optical Coherence | 2 | 2021 | 100 | 0.230 |
Why?
| | Mustard Gas | 1 | 2023 | 1 | 0.230 |
Why?
| | Corneal Ulcer | 1 | 2023 | 4 | 0.230 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 976 | 0.230 |
Why?
| | Dendritic Cells | 1 | 2024 | 133 | 0.230 |
Why?
| | alpha-MSH | 1 | 2023 | 17 | 0.230 |
Why?
| | Cell Count | 2 | 2020 | 147 | 0.220 |
Why?
| | Antigens, CD | 1 | 2024 | 219 | 0.220 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 252 | 0.220 |
Why?
| | Corneal Dystrophies, Hereditary | 1 | 2022 | 1 | 0.210 |
Why?
| | Trigeminal Nerve Diseases | 1 | 2022 | 3 | 0.210 |
Why?
| | Humans | 15 | 2023 | 49974 | 0.210 |
Why?
| | Keratitis, Herpetic | 1 | 2022 | 2 | 0.210 |
Why?
| | Tissue Donors | 2 | 2020 | 111 | 0.210 |
Why?
| | Aged | 6 | 2020 | 9310 | 0.210 |
Why?
| | Keratitis | 1 | 2022 | 11 | 0.210 |
Why?
| | Corneal Neovascularization | 1 | 2022 | 1 | 0.210 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2022 | 22 | 0.210 |
Why?
| | Descemet Membrane | 1 | 2021 | 2 | 0.200 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 129 | 0.200 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 75 | 0.200 |
Why?
| | Disease Models, Animal | 3 | 2022 | 1455 | 0.200 |
Why?
| | Edema | 1 | 2021 | 67 | 0.190 |
Why?
| | Corneal Pachymetry | 1 | 2020 | 5 | 0.190 |
Why?
| | Lasers, Excimer | 1 | 2020 | 3 | 0.190 |
Why?
| | Acanthamoeba | 1 | 2020 | 2 | 0.190 |
Why?
| | Benzamidines | 1 | 2020 | 5 | 0.180 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 9 | 0.180 |
Why?
| | Ophthalmic Solutions | 1 | 2020 | 18 | 0.180 |
Why?
| | Stem Cell Transplantation | 2 | 2021 | 181 | 0.180 |
Why?
| | Postoperative Period | 1 | 2020 | 170 | 0.180 |
Why?
| | Middle Aged | 5 | 2020 | 12069 | 0.170 |
Why?
| | Retinal Vessels | 1 | 2019 | 12 | 0.170 |
Why?
| | Intraocular Pressure | 1 | 2019 | 53 | 0.170 |
Why?
| | Hypercholesterolemia | 1 | 2019 | 36 | 0.170 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2019 | 1 | 0.170 |
Why?
| | Retinal Ganglion Cells | 1 | 2019 | 13 | 0.170 |
Why?
| | Apolipoproteins E | 1 | 2019 | 56 | 0.170 |
Why?
| | Retinal Artery | 1 | 2019 | 4 | 0.170 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 377 | 0.170 |
Why?
| | Adult | 5 | 2020 | 13236 | 0.160 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2018 | 75 | 0.160 |
Why?
| | RNA, Messenger | 2 | 2019 | 1105 | 0.160 |
Why?
| | Female | 8 | 2023 | 26472 | 0.160 |
Why?
| | Norepinephrine | 1 | 2018 | 107 | 0.150 |
Why?
| | Ophthalmic Artery | 1 | 2017 | 3 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2020 | 339 | 0.150 |
Why?
| | Vasodilator Agents | 1 | 2017 | 96 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1376 | 0.140 |
Why?
| | Regeneration | 1 | 2017 | 72 | 0.140 |
Why?
| | Oxidative Stress | 1 | 2019 | 770 | 0.130 |
Why?
| | Postoperative Complications | 1 | 2021 | 984 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2024 | 96 | 0.120 |
Why?
| | Aging | 1 | 2019 | 687 | 0.120 |
Why?
| | Signal Transduction | 1 | 2018 | 1618 | 0.100 |
Why?
| | Corneal Topography | 2 | 2020 | 6 | 0.090 |
Why?
| | Young Adult | 1 | 2020 | 3958 | 0.090 |
Why?
| | Adoptive Transfer | 1 | 2024 | 40 | 0.060 |
Why?
| | Interleukin-10 | 1 | 2024 | 84 | 0.060 |
Why?
| | Mice, Inbred C3H | 1 | 2024 | 83 | 0.060 |
Why?
| | Tissue Preservation | 1 | 2023 | 7 | 0.060 |
Why?
| | Mechlorethamine | 1 | 2023 | 4 | 0.060 |
Why?
| | Cytoprotection | 1 | 2023 | 35 | 0.060 |
Why?
| | Neutrophil Infiltration | 1 | 2023 | 26 | 0.060 |
Why?
| | Cell Movement | 1 | 2024 | 247 | 0.060 |
Why?
| | Antigen-Presenting Cells | 1 | 2023 | 26 | 0.060 |
Why?
| | Streptozocin | 1 | 2023 | 23 | 0.060 |
Why?
| | Microscopy, Confocal | 1 | 2023 | 88 | 0.060 |
Why?
| | Vision Disorders | 1 | 2023 | 57 | 0.050 |
Why?
| | Monocytes | 1 | 2023 | 131 | 0.050 |
Why?
| | Fluorescein | 1 | 2022 | 8 | 0.050 |
Why?
| | Eye Pain | 1 | 2022 | 4 | 0.050 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2022 | 9 | 0.050 |
Why?
| | Trigeminal Ganglion | 1 | 2022 | 1 | 0.050 |
Why?
| | Substance P | 1 | 2022 | 27 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2022 | 12 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2022 | 95 | 0.050 |
Why?
| | Wound Healing | 1 | 2023 | 204 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2022 | 177 | 0.050 |
Why?
| | Phenotype | 1 | 2024 | 729 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2023 | 269 | 0.050 |
Why?
| | Macrophages | 1 | 2023 | 363 | 0.050 |
Why?
| | Photorefractive Keratectomy | 1 | 2020 | 2 | 0.050 |
Why?
| | Cell Line | 1 | 2023 | 1000 | 0.050 |
Why?
| | Re-Epithelialization | 1 | 2020 | 1 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2020 | 18 | 0.050 |
Why?
| | Stem Cells | 1 | 2021 | 171 | 0.040 |
Why?
| | Hypertrophy | 1 | 2020 | 50 | 0.040 |
Why?
| | Prednisolone | 1 | 2020 | 55 | 0.040 |
Why?
| | Cadaver | 1 | 2020 | 97 | 0.040 |
Why?
| | Perfusion | 1 | 2019 | 48 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2021 | 209 | 0.040 |
Why?
| | Gene Expression | 1 | 2022 | 609 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 56 | 0.040 |
Why?
| | Eye Proteins | 1 | 2019 | 17 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2019 | 60 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 201 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 322 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 221 | 0.040 |
Why?
| | RNA | 1 | 2019 | 170 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2019 | 181 | 0.040 |
Why?
| | Acetylcholine | 1 | 2017 | 54 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2017 | 26 | 0.040 |
Why?
| | Potassium Channels | 1 | 2017 | 31 | 0.040 |
Why?
| | Catalase | 1 | 2017 | 67 | 0.040 |
Why?
| | Blood Pressure | 1 | 2019 | 512 | 0.040 |
Why?
| | Cell Survival | 1 | 2019 | 600 | 0.040 |
Why?
| | Cytokines | 1 | 2019 | 612 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 2607 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2017 | 253 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1557 | 0.030 |
Why?
| | Risk Factors | 1 | 2022 | 3613 | 0.030 |
Why?
| | Models, Biological | 1 | 2017 | 727 | 0.030 |
Why?
| | Time Factors | 1 | 2019 | 2903 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2020 | 5141 | 0.020 |
Why?
|
|
Musayeva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|